The use of metformin in the battle against chronic kidney disease and its cardiovascular complications. University of Antwerp
Over the past decades metformin is the optimal first-line drug for type 2 diabetes mellitus (T2DM) with 70 million prescriptions in the United States in 2013. Only in the last few years, it has become clear that metformin exerts benign pleiotropic actions beyond its prescribed use and ongoing investigations focus on its anti-ageing and anti-cancer properties. Recent data from preclinical and clinical studies are additionally pointing towards a ...